Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Targeting BCL-XL with a Novel VHL-Based BCL-XL Degrader DT-2216 in Pre-Clinical JAK2 -Mutant AML Post-MPN Models

Zhe WANG, Qi Zhang, Anna Skwarska, Cassandra L. Ramage, Guangrong Zheng, Kira Gritsman, Kapil N. Bhalla, Naveen Pemmaraju, Daohong Zhou, Jeffrey W Tyner, Marina Y. Konopleva

Blood (2023) 142 (Supplement 1): 4154.

https://doi.org/10.1182/blood-2023-178813

Published: 2023

Journal Articles

Enriched Signalling Pathways in Venetoclax-Relapsed Chronic Lymphocytic Leukemia (CLL) Cells and Targeting Using a Protac-Based Bcl-2/Bcl-Xl Degrader

Daisy Diaz Rohena, Arnau Peris Cuesta, Bailey Slawin, Janani Ravikrishnan, Chaomei Liu, Charmelle Williams, Wanyi Hu, Peiyi Zhang, Philip Thompson, William G. Wierda, Nitin Jain, Sachet Shukla, Guangrong Zheng, Daohong Zhou, Jennifer A. Woyach, Deepa Sampath

Blood (2023) 142 (Supplement 1): 4195.

https://doi.org/10.1182/blood-2023-188250

Published: 2023

Journal Articles

Targeting Venetoclax Resistant CLL Using a Protac-Based BCL-2/BCL-XL Degrader

Daisy Diaz Rohena, Bailey Slawin, Janani Ravikrishnan, Chaomei Liu, Wanyi Hu, Peiyi Zhang, Philip A. Thompson, William G. Wierda, Nitin Jain, Guangrong Zheng, Daohong Zhou, Jennifer A. Woyach, Deepa Sampath

Blood (2022) 140 (Supplement 1): 497–498.

https://doi.org/10.1182/blood-2022-168345

Published: 2022

Journal Articles

Dual BCL-XL/2 Protac 753B Not Only Potently Induces Apoptosis in Venetoclax-Resistant Primary AML Cells but Also Effectively Eliminates Chemotherapy-Induced Senescent AML Cells

Yannan Jia, Lina Han, Cassandra L Ramage, Connie C. Weng, Lei Yang, Simona Colla, Helen Ma, Weiguo Zhang, Michael Andreeff, Naval Daver, Nitin Jain, Naveen Pemmaraju, Kapil N. Bhalla, Satu Mustjoki, Peiyi Zhang, Guangrong Zheng, Daohong Zhou, Qi Zhang, Marina Konopleva

Blood (2022) 140 (Supplement 1): 3347–3349.

https://doi.org/10.1182/blood-2022-164541

Published: 2022

Journal Articles

Study of the Dynamics and Diversity of Hematopoietic Stem Cells during Aging and Senolytic Drug Treatment Using Single Cell Transcriptomics

Bowen Yan, Guangrong Zheng, Daohong Zhou, Olga A Guryanova

Blood (2022) 140 (Supplement 1): 5760–5761.

https://doi.org/10.1182/blood-2022-170033

Published: 2022

Journal Articles

Targeting Venetoclax-Resistant CLL By Bcl-XL Degradation

Daisy Diaz Rohena, Janani Ravikrishnan, Chaomei Liu, Guangrong Zheng, Daohong Zhou, Peiyi Zhang, William G. Wierda, Nitin Jain, Jennifer A. Woyach, Deepa Sampath

Blood (2021) 138 (Supplement 1): 2252.

https://doi.org/10.1182/blood-2021-151982

Published: 2021

Journal Articles

Targeting BCL-XL and BCL-2 By Protac 753B Effectively Eliminates AML Cells and Enhances Efficacy of Chemotherapy By Targeting Senescent Cells

Yannan Jia, Qi Zhang, Weiguo Zhang, Michael Andreeff, Nitin Jain, Peiyi Zhang, Guangrong Zheng, Daohong Zhou, Marina Konopleva

Blood (2021) 138 (Supplement 1): 2230.

https://doi.org/10.1182/blood-2021-147535

Published: 2021

Journal Articles

DT2216, a BCL-XL Proteolysis Targeting Chimera (PROTAC), Is a Potent Anti T-Cell Lymphoma Agent That Does Not Induce Significant Thrombocytopenia

Yonghan He, MD, Raphael Koch, Vivekananda Budamagunta, Dongwen Lv, Sajid Khan, Xuan Zhang, Janet S Wiegand, Guangrong Zheng, David M. Weinstock, MD, Daohong Zhou

Blood (2019) 134 (Supplement_1): 303.

https://doi.org/10.1182/blood-2019-125820

Published: 2019

Journal Articles

Targeting BCL-XL By Protac DT2216 Effectively Eliminates Leukemia Cells in T-ALL Pre-Clinical Models

Qi Zhang, PhD, Sajid Khan, PhD, Xuan Zhang, Vinitha Mary Kuruvilla, MSc, Sanaz Ghotbaldini, Julia Wells, PhD, Natalia Baran, PhDMD, Tianyu Cai, PhD, Lina Han, PhD, Adolfo Ferrando, MD, PhD, Yong-Mi Kim, MD MPH, PhD, Guangrong Zheng, Daohong Zhou, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 3870.

https://doi.org/10.1182/blood-2019-124744

Published: 2019

Journal Articles

DT2216, a Synthetic Proteolytic Selectively Targeting Bcl-X L for Ubiquitination and Degradation in Tumor Cells but Not in Platelets, Is a Safer and More Potent Antitumor Agent Than Navitoclax

Sajid Khan, PhD, Xuan Zhang, BMBS, Dongwen Lv, PhD, Yonghan He, MD, Peiyi Zhang, MS, Xingui Liu, PhD, Dinesh Thummuri, PhD, Qi Zhang, PhD, Marina Y. Konopleva, MD PhD, Robert A. Hromas, MD, Guangrong Zheng, Daohong Zhou, MD

Blood (2018) 132 (Supplement 1): 2698.

https://doi.org/10.1182/blood-2018-99-114762

Published: 2018

NARROW

Targeting BCL-XL with a Novel VHL-Based BCL-XL Degrader DT-2216 in Pre-Clinical JAK2 -Mutant AML Post-MPN Models

Enriched Signalling Pathways in Venetoclax-Relapsed Chronic Lymphocytic Leukemia (CLL) Cells and Targeting Using a Protac-Based Bcl-2/Bcl-Xl Degrader

Targeting Venetoclax Resistant CLL Using a Protac-Based BCL-2/BCL-XL Degrader

Dual BCL-XL/2 Protac 753B Not Only Potently Induces Apoptosis in Venetoclax-Resistant Primary AML Cells but Also Effectively Eliminates Chemotherapy-Induced Senescent AML Cells

Study of the Dynamics and Diversity of Hematopoietic Stem Cells during Aging and Senolytic Drug Treatment Using Single Cell Transcriptomics

Targeting Venetoclax-Resistant CLL By Bcl-XL Degradation

Targeting BCL-XL and BCL-2 By Protac 753B Effectively Eliminates AML Cells and Enhances Efficacy of Chemotherapy By Targeting Senescent Cells

DT2216, a BCL-XL Proteolysis Targeting Chimera (PROTAC), Is a Potent Anti T-Cell Lymphoma Agent That Does Not Induce Significant Thrombocytopenia

Targeting BCL-XL By Protac DT2216 Effectively Eliminates Leukemia Cells in T-ALL Pre-Clinical Models

DT2216, a Synthetic Proteolytic Selectively Targeting Bcl-X L for Ubiquitination and Degradation in Tumor Cells but Not in Platelets, Is a Safer and More Potent Antitumor Agent Than Navitoclax

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only